1. Medical Management of HIV Among Transgender Adults

2. Medical Management of HIV Among Transgender Adults

5. CME Information

6. Nursing and Pharmacy Credits

7. Evaluations will be available in your IAS-USA My Activities page by 5 pm PT today. See the IAS–USA website for instructions on claiming CME, pharmacy, nursing, or pharmacotherapy credits, or a certificate of participation.

8. Grant Support for this Webinar

9. Navigating the Webinar

10. Poll 1

11. Poll 2

12. Poll 3

13. Medical Management of HIV Among Transgender Adults

14. Financial Relationships With Commercial Entities

15. Learning Objectives

16. Pretest Question 1

17. Pretest Question 2

18. Definitions

19. U.S. Transgender Population Size Estimates

20. Ascertaining Gender Identities

21. Estimated Prevalence of HIV and Sexual Behaviors in US Trans Population: A Systematic Review and Meta-Analysis,

23. Clients Served by the Ryan White HIV/AIDS Program, by Gender and Race/Ethnicity, 2017—United States and 3 Territoriesa

24. Viral Suppression among Clients Served by the Ryan White HIV/AIDS Program, by Gender, 2017—United States and 3 Territoriesa

25. Gender Affirmation and HIV Care

26. Provider Interactions and Viral Suppression

27. Provider Interactions and Viral Suppression

28. Provider Interactions and Viral Suppression

29. Gender-Affirmation (also called “transition”)

30. Binding, Tucking, Soft Tissue Fillers (Silicone)

31. Medical and Surgical Gender Affirmation

32. Clinical Guidelines and Standards of Care

33. CASE: Brittany

34. ARS 1: What do you need to do to meet her needs?

35. Initial Visits: Medical History and Labs

36. Sexual History

37. Initial Visits: Physical Exam

38. Feminizing Regimens: Estrogen + Anti-androgen

39. Effects of Feminizing Hormones

40. Cardiovascular Health

41. Cardiovascular Health

42. Bone Health

43. Bone Health

44. Case 2: Rodney

45. ARS 2: Does Rodney need additional testing before starting ART?

46. Masculinizing Hormone Regimens

47. Masculinizing Therapy

48. Hormone Therapy Monitoring

49. Interpreting Sex-Based Lab Values

50. Interpreting Sex-Based Lab Values (2)

51. Interpreting Sex-Based Risk Estimates

52. Case 3: Marta

53. ARS 3: What is a potential cause of Marisa’s hot flashes?

54. Drug – Drug Interactions

55. ART and Gender Affirming Hormone Therapy Interactions

56. Drug Interaction Concerns Affect Adherence

57. PrEP in Transgender Women: iPrEx

58. PrEP in Transgender Women: iPrEx

59. PrEP in Transgender Women: iPrEx

60. Sex hormones alter TDF/FTC Pharmacology

61. Sex hormones alter TDF/FTC Pharmacology in HIV

62. The iFACT study

63. The iFACT study

66. Summary of Data on PrEP among Trans Women

67. Summary of Data on PrEP among Trans Women

68. Little data on PrEP for Trans Men

69. I-BrEATHe study (UCSF)

70. CDC Recommendations for PrEP

71. PrEP for Trans People: Take Home

72. PrEP for Trans People: Take Home

73. PrEP for Trans People: Take Home

74. PrEP for Trans People: Take Home

75. Stigma is a Barrier to Engagment

76. Trans-Affirming Clinic Environments

77. Trans-Affirming Clinic Environments

78. Trans-Affirming Clinic Environments

79. Trans-Affirming Clinic Environments

80. Trans-Affirming Clinic Environments

81. Resources

82. Posttest Question 1

83. Posttest Question 2

84. Question-and-Answer

86. Evaluations will be available in your IAS-USA My Activities page by 5 pm PT today. See the IAS–USA website for instructions on claiming CME, pharmacy, nursing, or pharmacotherapy credits, or a certificate of participation.

87. Final Poll

90. Sexual Health, HIV Prevention, and Primary Care in 2019

93. Thank You